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Succinate in Dystrophic White Matter:
A Proton Magnetic Resonance
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A deficiency of succinate dehydrogenase is a rare cause of mitochondrial encephalomyopathy. Three patients, 2 sisters and
1 boy from an unrelated family, presented with symptoms and magnetic resonance imaging signs of leukoencephalopathy.
Localized proton magnetic resonance spectroscopy indicated a prominent singlet at 2.40ppm in cerebral and cerebellar
white matter not present in gray matter or basal ganglia. The signal was also elevated in cerebrospinal fluid and could be
identified as originating from the two equivalent methylene groups of succinate. Subsequently, an isolated deficiency of
complex II (succinate:ubiquinone oxidoreductase) was demonstrated in 2 patients in muscle and fibroblasts. One of the
sisters died at the age of 18 months. Postmortem examination showed the neuropathological characteristics of Leigh syn-
drome. Her younger sister, now 12 months old, is also severely affected; the boy, now 6 years old, follows a milder,
fluctuating clinical course. Magnetic resonance spectroscopy provides a characteristic pattern in succinate dehydrogenase
deficiency.
Ann Neurol 2002;52:38–46
Defects of oxidative phosphorylation give rise to
heterogeneous clinical symptoms ranging from isolated
organ dysfunction to multisystem disorder.1 Leigh syn-
drome and leukoencephalopathies are part of the spec-
trum of neurological diseases representing a common
neuropathological substrate to diverse genetic and bio-
chemical defects.2 Abnormalities of complexes I, III,
IV, and V resulting from defects of the mitochondrial
and nuclear genome have been identified as major
causes in these patients.
A deficiency of complex II represents a rare cause of
mitochondrial encephalomyopathy and may be associ-
ated with Leigh syndrome and leukodystrophy,3,4 late-
onset optic atrophy and ataxia,5 myopathy with exer-
cise intolerance,6,7 and isolated cardiomyopathy.8
Complex II (succinate:ubiquinone oxidoreductase,
E.C.1.3.5.1.) consists of the soluble active enzyme succi-
nate dehydrogenase (SDH) and two membrane-anchored
proteins (SDHC and SDHD). SDH is composed of a
flavoprotein and an iron-sulfur protein subunit (SDHA
and SDHB). It catalyzes the oxidation of succinate to fu-
marate in the Krebs cycle and carries electrons to the
ubiquinone pool of the respiratory chain.9
In contrast to all other complexes of the mitochon-
drial respiratory chain, all four subunits are encoded by
nuclear DNA. The complementary DNAs of the fla-
voprotein and iron-sulfur protein subunit have been
cloned and sequenced.10,11
We studied 2 sisters and 1 boy from 2 unrelated
families with clinical symptoms and magnetic reso-
nance imaging (MRI) signs of a progressive leukoen-
cephalopathy. After the detection of accumulated suc-
cinate in cerebral and cerebellar white matter by proton
magnetic resonance spectroscopy (MRS), a deficiency
of complex II was demonstrated biochemically. Patient
1 was previously discussed in a review article.12
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Patients and Methods
Family History of Patients 1 and 2
A pedigree of this family is depicted in Figure 1. Patients 1
and 2 were the second and fifth children of consanguineous
(first cousins), healthy parents of Turkish origin. Their oldest
brother is healthy. Their mother’s third gestation was a twin
pregnancy. One twin died in utero, and the other twin boy
was born prematurely at 26 weeks of gestation. He suffered
from intraventricular hemorrhaging and now has spastic di-
plegia.
Patient 1
This girl was born at term without complications. Her birth
weight of 2,470g (3rd percentile) pointed to intrauterine
growth retardation; her length and head circumference were
normal. Although her length and head circumference in-
creased within normal range, her weight remained below the
3rd percentile. Psychomotor development was normal until
the age of 10 months. She sat at 7 months, crawled at 8
months, and pulled up to standing at 9 months. Parents first
became worried by dysphoric behavior before—without pre-
ceding infection—a rapidly progressive loss of all motor skills
was observed at 10 months. Within 3 weeks, she was unable
to crawl or sit or hold her bottle. Her mental functions were
preserved. On admission at 11 months, the child was ex-
tremely restless and irritable. There was marked spasticity
and hyperreflexia in her legs and arms; Babinski’s sign was
present. Funduscopy was normal. Physical examination indi-
cated no abnormalities apart from dystrophy (body weight,
1.7kg below the 3rd percentile; height, 10th percentile; head
circumference, 75th percentile). Electrocardiogram and echo-
cardiography were normal.
After demonstration of an isolated complex II deficiency
(discussed later), riboflavin, coenzyme Q, and carnitine were
supplemented. However, a progressive deterioration with in-
creasing spasticity and signs of brainstem dysfunction was
observed. At the age of 18 months, the girl died as a result of
multiorgan failure with severe lactic acidosis during a febrile
infection.
Patient 2
This girl, the younger sister of Patient 1, was born after an
uneventful pregnancy and delivery at term. Prenatal diagno-
sis for complex II deficiency was not sought by the parents.
She was small for gestational age (birth weight, 1,740g), and
her weight remained below the 3rd percentile. Motor and
mental development was normal during the first months:
head control at 3 weeks, sitting at 7 months, and crawling at
8 months. She produced syllables and single words. As for
her sister, dysphoric behavior caused early concern. Without
any particular preceding event, a rapid motor deterioration
occurred at the age of 10 months. She lost all motor skills
within 4 weeks. On admission to our hospital, her body
weight and length were below the 3rd percentile, and her
head circumference was at the 3rd percentile. Social skills
were adequate for age. Neurological examination showed a
severe spastic paresis predominantly affecting her legs and
dystonic posturing of her fingers. Funduscopy was normal.
Electrocardiogram and echocardiography were normal.
Patient 3
This boy was the first of three children of unrelated Norwe-
gian parents coming from neighboring areas. His siblings
were healthy. The boy was delivered by caesarean section at
27 weeks of gestation as a result of his mother’s preeclamp-
sia. His birth weight was 820g, and his Apgar scores were 6,
8, and 8. He showed early visual contact and reactive smil-
ing, crawled at 11 months, and walked unsupported at 16
months. He spoke his first words before 12 months of age.
From the age of 20 months onward, increasing spasticity and
clumsiness were observed, with a gradual loss of all major
motor skills over a period of 16 months. He lost active
speech but was able to understand others and appeared un-
affected in his cognitive functions.
From then on, a slow improvement in most skills oc-
curred spontaneously. He could sit up, learned to crawl
again, and restarted to eat independently. He retained clini-
cal signs of pyramidal tract lesion. His head circumference
has followed the 25th percentile. At present (6 years of age),
he is able to walk with support and to say a few words.
Laboratory Investigations
Biochemical studies including routine blood tests and assess-
ments of amino acids and organic acids in urine, lysosomal
enzymes, and very long-chain fatty acids were normal in Pa-
tients 1 and 3. No evidence was found for an infectious dis-
order. Plasma lactate (normal  2.1mmol/L) was only occa-
sionally elevated to 2.7, 2.8, and 2.4mmol/L in Patients 1, 2,
and 3, respectively.
In cerebrospinal fluid, lactate was mildly increased to
2.3mmol/L (normal  2.1) in Patient 1 and was normal in
Patient 3. The total protein content was normal in Patient 1
and mildly elevated to 33mg/dL (normal  32) in Patient 3.
Fig 1. Pedigree of the family of Patients 1 and 2.
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Neuropathological Findings in Patient 1
Brain weight was 1,190g (normal: mean, 970g; SD, 160g).
No abnormalities were noted on external inspection. On sec-
tioning, all ventricles were compressed. There were several
grayish, soft, sharply delineated lesions in central parts of the
corpus callosum and the right internal capsule; in the walls
of the third ventricle; in the medulla oblongata, cerebellar
peduncles, and vermis; in the white matter of the cerebellar
hemispheres; and in the upper cervical spinal cord. A large,
symmetric, grayish softening of the centrum semiovale was
observed.
Microscopic examination of white matter indicated loss of
myelin, marked spongiform degeneration, astrocytosis, and
intense vascular proliferation. Gray matter was affected to a
lesser extent; neurons and axons were relatively preserved.
Histopathological features and topic patterns of this multifo-
cal spongiform encephalomyelopathy were consistent with
Leigh syndrome.
Magnetic Resonance Spectroscopy
Written informed consent was obtained from the parents.
Fully relaxed short-echo-time proton magnetic resonance
(MR) spectra (TR/TE  6,000/20msec, 64 accumulations)
were acquired with the use of a single-voxel stimulated echo
acquisition mode localization sequence13 and the standard im-
aging head coil at 2.0T (Siemens Magnetom Vision, Erlangen,
Germany). Volumes of interest were selected from T1-
weighted (3D FLASH)—and, in Patients 2 and 3, T2-
weighted (fast spin echo)—images, with sizes ranging from 4.1
to 12.5ml. Spectral evaluation and quantification of absolute
metabolite concentrations were accomplished as described else-
where.12 Previous studies of regional age dependencies of ce-
rebral metabolites14 provided age-matched controls. Major
detectable metabolites include the neuroaxonal markers15
N-acetylaspartate (NAA) and N-acetylaspartylglutamate
(tNAA), creatine and phosphocreatine (tCr) as ubiquitous
compounds linked to energy metabolism, choline-containing
compounds involved in membrane turnover, the glial (astro-
cytic) marker16 myo-inositol, and lactate as an intermediate
product of nonoxidative glucose consumption. In addition,
high-resolution, one-dimensional and two-dimensional,
J-resolved proton MRS studies of cerebrospinal fluid served
to confirm the spectral assignment of the succinate proton
resonance.
Histopathological Studies (Skeletal Muscle)
Biopsies from M. vastus lateralis were performed in Patients
1 and 3. Histochemical analyses were carried out according
to routine protocols.
Biochemical Investigations (Skeletal Muscle
and Fibroblasts)
The respiratory chain enzyme complex activities were mea-
sured according to the following methods: NADH:ubiqui-
none oxidoreductase, as described by Smeitink and col-
leagues;17 succinate:cyt c oxidoreductase; and SDH as
described by Fischer and colleagues.18 Decylubiquinol: cyt
c oxidoreductase was measured with decylubiquinol and
horse cytochrome c as the electron donor and acceptor, re-
spectively. Tween 20 (0.04%) was added to break the mi-
tochondria (H.A.C.M. Bentlage, unpublished data, 1996).
Cytochrome c oxidase (Cox) was determined (with slight
modifications) as described by Cooperstein and Lazarow,19
and citrate synthase was determined as described by Srere.20
For cultured fibroblasts, enzyme measurements were per-
formed in mitochondria-enriched fractions; for muscle tis-




PATIENTS 1 AND 2. In both Patients 1 and 2, MRI was
first performed at 11 months of age. Although gray
matter, basal ganglia, and ventricles were normal, both
patients showed extensive T2-hyperintensities in cen-
tral parts of supratentorial white matter with predom-
inance in frontal and occipital lobes, as demonstrated
in Figures 2A and B and Figure 3A, respectively. De-
marcation to peripheral normal-appearing white matter
was vague, and subcortical U-fibers were spared. Figure
3B depicts a distinct T1-hypointensity of cerebellar
white matter bilaterally in Patient 2, which occurred
earlier than in Patient 1 (not shown). In addition,
follow-up investigations of Patient 1 at 13 and 17
months of age indicated further increases in white mat-
ter intensities in T2-weighted images.
PATIENT 3. MRI at the age of 24 months showed
widespread T2-hyperintensities in cerebral periven-
tricular white matter mainly involving frontal and oc-
cipital lobes. The corpus callosum and pons were also
affected; subcortical U-fibers were spared. Gray matter
and basal ganglia were normal. Follow-up MRI inves-
tigations at the ages of 32, 39, and 50 months showed
gradual progression of these signal changes to more pe-
ripheral regions of supratentorial white matter and
small cystic lesions in affected areas. T1- and T2-
weighted images of the last examination are shown in
Figures 4A and B.
Magnetic Resonance Spectroscopy
PATIENT 1. As shown in Figures 2C to F, MR spectra
from different brain regions of Patient 1 were obtained
at the age of 13 months for left and right white matter
(see Figs 2C and D, respectively), parieto-occipital gray
matter (see Fig 2E), and basal ganglia (see Fig 2F).
Quantitative analyses of absolute metabolite concentra-
tions are summarized in Table 1 for the examinations
at 13 and 17 months of age.
The most obvious result is the occurrence of a prom-
inent resonance at a frequency of 2.40ppm in proton
MR spectra of white matter, which is not present in
the normal human brain. Because this signal was also
observed in high-resolution proton MR spectra of ce-
rebrospinal fluid obtained from this patient, two-
dimensional, J-resolved MRS techniques allowed its
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identification as a singlet proton resonance not coupled
to other nuclear spins. Together with the chemical
shift position, it may, therefore, be assigned to the four
protons of the two equivalent methylene groups of suc-
cinate HOOCOCH2OCH2OCOOH.
In addition, both spectra (see Figs 2C and D) and
quantified metabolite concentrations (see Table 1)
from cerebral white matter showed markedly reduced
levels of tNAA and tCr as well as elevated lactate. The
latter finding was even more pronounced at a
follow-up MRS investigation at the age of 17 months.
The observation of a mild but significant increase of
myo-inositol at this stage agrees with the occurrence of
astrocytosis.
In contrast to white matter, no succinate and lactate
were detectable in cortical gray matter (see Fig 2E) and
basal ganglia (see Fig 2F). With the two MRS exami-
nations taken together, gray matter metabolite levels
turned out to be rather unaffected apart from a mild
reduction of tNAA.
Fig 2. Patient 1. (A, B) T2-weighted magnetic resonance (MR) images at 11 months of age and (C–F) localized proton MR spec-
tra (single-voxel stimulated echo acquisition mode, TR/TE  6,000/20ms, 64 accumulations) at 13 months of age from (C, D)
left- and right-hemispheric parieto-occipital white matter, (E) paramedian parietal gray matter, and (F) basal ganglia. Metabolites
refer to N-acetylaspartate and N-acetylaspartylglutamate (tNAA), creatine and phosphocreatine (tCr), choline-containing compounds
(Cho), myo-inositol (Ins), lactate (Lac), and succinate (Suc). The spectral amplitudes of white matter (WM) are scaled down by a
factor of 2 relative to those of gray matter (GM) and basal ganglia (BG).
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PATIENT 2. In general, proton MRS examinations of
Patient 2 at 12 months of age showed the same pattern
of metabolic abnormalities found in her sister (Patient
1). As demonstrated in Figure 3 and quantified in Ta-
ble 2, both cerebral (see Fig 3C) and cerebellar white
matter (see Fig 3D) showed decreased levels of tNAA
and tCR as well as elevated lactate and prominent res-
onances from succinate. In this girl, gray matter was
completely normal. In basal ganglia, there were no ab-
normalities apart from elevated tCR, as in her sister.
PATIENT 3. Proton MR spectra of cerebral white and
gray matter of Patient 3 at 50 months of age are shown
in Figures 4C and D. Table 3 summarizes correspond-
ing metabolite concentrations and again confirms the
presence of succinate and elevated lactate in cerebral
white matter, although at slightly lower levels than in
Patients 1 and 2. Furthermore, and in agreement with
Patients 1 and 2, white matter showed decreased con-
centrations of tNAA and tCr. The significant enhance-
ment of myoinositol suggests the presence of astrocy-
tosis. The metabolite patterns of cortical gray matter
and basal ganglia were normal except for a mild but
significant decrease of tCr in basal ganglia.
Skeletal Muscle Studies
Muscle biopsy showed a weak SDH reaction with re-
spect to normal controls in Patient 1. COX activity
was normal. Reactions to SDH and COX were normal
in Patient 3.
Biochemical Analysis
Biochemical analysis of skeletal muscle tissue (M. vas-
tus lateralis) and cultured skin fibroblasts in Patient 1
and of fibroblasts in Patient 3 demonstrated severely
decreased activities of SDH and succinate:cyt c oxi-
doreductase (Table 4). The activities of complexes I,
III, and IV were normal in both children. As Patient 2
was examined only recently, an investigation of the ac-
tivities of her respiratory chain enzymes are still under-
way.
Discussion
During this study of 3 children with a so far unclassi-
fied leukoencephalopathy, strongly elevated concentra-
tions of succinate in cerebral and cerebellar white mat-
ter were detected with localized proton MRS.
Biochemical investigations confirmed a deficiency of
Fig 3. Patient 2 (sister of Patient 1). (A, B) T2- and T1-weighted magnetic resonance (MR) images and (C, D) localized proton
MR spectra at 12 months of age from (C) left-hemispheric parieto-occipital white matter (WM; scaled down by a factor of 2) and
(D) right-hemispheric cerebellum (Cereb). For other details, see Figure 2.
42 Annals of Neurology Vol 52 No 1 July 2002
Fig 4. Patient 3 (unrelated to Patients 1 and 2). (A, B) T2- and T1-weighted magnetic resonance (MR) images and (C, D) local-
ized proton MR spectra at 50 months of age from (C) left-hemispheric parieto-occipital white matter (WM) and paramedian pari-
etal gray matter (GM; scaled down by a factor of 2). For other details, see Figure 2.
Table 1. Cerebral Metabolite Concentrations (mM) of Patient 1 at 13 and 17 Months of Age
tNAA tCr Cho Ins Lac Suc
White matter
13 months
LP 1.9c 2.9c 1.8 3.7 2.4 8.1
RP 3.1c 3.5b 1.9 3.8 3.7 7.0
17 months
LP 2.0c 1.9c 1.4 3.9 6.9 8.7
RP 2.9c 3.4c 1.7 4.9b 4.7 7.1
Control (n  14)a 6.5 0.5 5.0 0.5 1.8 0.2 3.5 0.6 — —
Gray matter
13 months
PMP 5.8b 6.3 1.5 5.3 — —
17 months
PMP 6.2 6.5 1.2 4.7 — —
Control (n  11)a 7.5 0.7 6.4 0.8 1.2 0.2 4.4 0.9 — —
Basal ganglia
13 months
Right 7.0 8.7b 2.2 4.4 — —
Control (n  8)a 6.9 0.7 7.6 0.5 1.9 0.2 3.7 0.5 — —
aMean  standard deviation.
b2 standard deviations from control.
c3 standard deviations from control.
LP  left parietal; RP  right parietal; PMP  paramedian parietal.
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SDH, the active part of complex II of the oxidative
phosphorylation system, in 2 patients.
So far, the main findings of proton MRS studies of
disorders of oxidative phosphorylation are characterized
by the observation of elevated lactate with regional
variation21–23 and decreased tNAA as a sign of vital
neuroaxonal tissue damage or loss. More specific met-
abolic abnormalities pointing to a particular metabolic
disturbance as the cause of a mitochondrial encephalo-
myopathy have not been reported. For the first time,
this work demonstrates the occurrence of strongly ele-
vated succinate in white matter as a result of SDH de-
ficiency.
Because of its low concentration under physiological
conditions, succinate is not detectable by proton MRS
of a healthy brain.14 It has been identified by in vivo
MRS in brain abscesses as an intermediate product of
bacterial metabolism,24,25 in certain cerebral infec-
tions,26,27 and in radiation-induced brain injuries.28
Complex II (succinate:ubiquinone oxidoreductase)
deficiency accounts for approximately 2% of mito-
chondrial encephalomyopathies.29,30 Among a wide
range of clinical presentations, leukodystrophy and
Leigh syndrome have been reported to be associated
with complex II deficiency.31,32
Although Patient 3 showed a milder clinical course
and succinate and lactate concentrations in affected
white matter not as high as the 2 sisters had (as mea-
sured by MRS), white matter changes as shown on
MRI were more extensive than in the girls. The char-
acteristic topological MRI pattern of Leigh syndrome
with the involvement of basal ganglia and brainstem
was not present in any of the patients. The MRS-
detected metabolite levels of gray matter were mostly
Table 2. Cerebral Metabolite Concentrations (mM) of Patient 2 at 12 Months of Age
tNAA tCr Cho Ins Lac Suc
White matter
LP 3.9c 3.5b 1.6 3.2 4.8 8.3
Control (n  14)a 6.5 0.5 5.0 0.5 1.8 0.2 3.5 0.6 — —
Gray matter
PMP 8.0 7.0 1.5 5.4 — —
Control (n  11)a 7.5 0.7 6.4 0.8 1.2 0.2 4.4 0.9 — —
Basal ganglia
Left 7.8 9.0b 1.8 3.7 — —
Control (n  8)a 6.9 0.7 7.6 0.5 1.9 0.2 3.7 0.5 — —
Cerebellum
Right 5.1 6.7 1.8 5.2 4.6 3.7
Control (n  4)a 5.7 0.5 7.8 0.6 1.9 0.3 6.6 1.2 — —
aMean  standard deviation.
b2 standard deviations from control.
c3 standard deviations from control.
LP  left parietal; RP  right parietal; PMP  paramedian parietal.
Table 3. Cerebral Metabolite Concentrations (mM) of Patient 3 at 50 Months of Age
tNAA tCr Cho Ins Lac Suc
White matter
LP 2.9c 3.3c 1.7 5.2b 1.7 1.3
RP 3.8c 4.1b 1.9 5.8c 1.5 0.5
Control (n  12)a 7.2 0.7 5.0 0.4 1.9 0.2 3.7 0.6 — —
Gray matter
PMP 7.9 6.2 1.2 5.0 — —
Control (n  16)a 8.2 0.9 6.4 0.7 1.1 0.2 4.7 0.4 — —
Basal ganglia
Right 6.9 6.1b 1.8 4.6 — —
Control (n  13)a 8.0 0.8 7.9 0.6 1.8 0.2 3.8 0.9
aMean  standard deviations.
b2 standard deviations from control.
c3 standard deviations from control.
LP  left parietal; RP  right parietal; PMP  paramedian posterior
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within normal ranges, including lactate in basal gan-
glia.
The different clinical courses observed in our pa-
tients cannot be explained by the biochemical findings
presented. The residual activity of complex II measured
in fibroblasts of Patients 1 and 3 is similarly low. No
information about the residual activity in other tissues,
such as the brain, is available. A presumed difference in
protein subunit defects might influence the phenotype,
but these investigations are not yet completed. Pro-
found deficiencies in complex II activity resulting from
mutations in the flavoprotein gene of SDH are re-
ported to present as Leigh syndrome with characteristic
basal ganglia pathology.33
To our knowledge, this is the first report of highly
elevated concentrations of succinate in proton MR
spectra of the brain in disorders of the oxidative phos-
phorylation system. These observations of a character-
istic metabolic abnormality for complex II deficiencies
illustrate the unique potential of proton MRS as a
noninvasive tool for studying disorders of brain meta-
bolism. Taken together, there are now at least four
neurometabolic disorders with specific MRS findings:
Canavan’s disease (elevated tNAA),34 NAA deficiency
(lack of tNAA),35 disorders of creatine metabolism
(lack of tCr),36 and SDH deficiency as identified here.
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